Two Sigma Securities’s Aldeyra Therapeutics ALDX Stock Holding History

Two Sigma Securities’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-11,002	Closed	-$42.1K	–	1350
2025 Q2	$42.1K	Buy	+11,002	New	+$28.4K	0.01%	1126
2024 Q1	–	Sell	-15,294	Closed	-$53.7K	–	2913
2023 Q4	$53.7K	Buy	+15,294	New	+$47.2K	﹤0.01%	2594
2023 Q1	–	Sell	-22,387	Closed	-$156K	–	2601
2022 Q4	$156K	Buy	+22,387	New	+$128K	﹤0.01%	2003
2019 Q2	–	Sell	-13,507	Closed	-$122K	–	2049
2019 Q1	$122K	Buy	+13,507	New	+$115K	﹤0.01%	1547
2017 Q4	–	Sell	-50,728	Closed	-$365K	–	1713
2017 Q3	$365K	Buy	+50,728	New	+$265K	0.03%	331

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Two Sigma Securities's ALDX Position: Q3 2025 in Review

Two Sigma Securities sold out of Aldeyra Therapeutics (ALDX) in Q3 2025, closing a stake of 11,002 shares — an estimated $42.1K sold.

Two Sigma Securities first reported a position in ALDX in Q3 2017 and held it in 5 quarters. The position peaked at $365K in Q3 2017. 130 funds tracked by Wall St. Rank hold ALDX as of Q3 2025.

Two Sigma Securities reported no remaining Aldeyra Therapeutics position as of Q3 2025 after selling out during the quarter.
Two Sigma Securities sold 11,002 Aldeyra Therapeutics shares in Q3 2025, an estimated $42.1K.
Two Sigma Securities first reported a position in Aldeyra Therapeutics in Q3 2017 and held it in 5 quarters.
Two Sigma Securities's Aldeyra Therapeutics position peaked at $365K in Q3 2017.
130 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2025.

Based on Two Sigma Securities's 13F filing for Q3 2025, filed 14 Nov 2025.